Peak Bio Inc. (PKBO)
0.02
null (null%)
At close: Nov 14, 2024, 8:00 PM
undefined% (1D)
| Bid | n/a |
| Market Cap | 520.31K |
| Revenue (ttm) | 75.19K |
| Net Income (ttm) | -3.32M |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | -0.16071428571428573 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 0 |
| Avg. Volume (20D) | 0 |
| Open | undefined |
| Previous Close | undefined |
| Day's Range | 0.02 - 0.02 |
| 52-Week Range | 0.02 - 0.02 |
| Beta | 1.78 |
About PKBO
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 15, 2021
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PKBO
Website https://peak-bio.com
